Metabolic effects of telmisartan Review article
Article Sidebar
Published:
Jun 30, 2014
Keywords:
telmisartan, metabolic syndrom, cardiovascular risk
Main Article Content
Abstract
Angiotensin receptor AT1 antagonist are one of the five main hypotensive drugs. In has been proven that telmisartan effectively reduce global cardiovascular risk in patient with high cardiovascular risk at baseline. Recently the are more and more studies show potential metabolic effects of telmisartan. In this article we review the most important studies of telmisartan – classic studies like ONTARGET and new one, concern its metabolic potential effects.
Downloads
Download data is not yet available.
Article Details
How to Cite
Wójcik , D., Wełnicki , M., & Mamcarz , A. (2014). Metabolic effects of telmisartan. Cardiology in Practice, 8(2), 21-25. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1534
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Sznajderman M.: Zasady farmakologicznego leczenia nadciśnienia tętniczego. W: Podstawy farmakoterapii. Kostowski W., Herman Z. (red.). PZWL, wyd. III, Warszawa 2008.
2. Matsusaka T., Ichikawa I.: Biological functions of angiotensin and its receptors. Ann. Rev. Physiol. 59: 395-412.
3. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol. Pol. 2013; 71(supl. III): 27-118.
4. McClellan K.J., Markham A.: Telmisartan. Drugs 1998; 56: 1039-1044.
5. Yamagishi S., Takeuchi M.: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses 2005; 64(3): 476-478.
6. Yamagishi S., Nakamura K., Matsui T.: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr. Mol. Med. 2007; 7(5): 463-9.
7. Shiota A., Shimabukuro M., Fukuda D.: Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. Eur. J. Pharmacol. 2012; 692(1-3): 84-90.
8. Stangier J., Su C.A., Roth W.: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res. 2000; 28(4): 149-167.
9. Boehringer Ingelheim. Micardis (telmisartan) tablets prescribing information. Ridgefield, CT; 5 marca 2004.
10. The ONTAGRET Investigators. Telmisartan, Ramipril, or Both In Patients at High Risk for Vascular Events. N. Engl. J. Med. 2008; 358(15): 1547-1559.
11. Yusuf S., Sleight P., Pogue J.: The Heart Outcome Prevention Evaluation Study Investigators: Effect of angiotensin–converting enzyme, ramipril on cardiovascular events in high–risk patients. N. Engl. J. Med., 2000; 342: 145-153
12. Gerstein H.C., Bosch J., Pogue J. et al.: Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996; 19(11): 1225-1228.
13. Yusuf S., Teo K., Anderson C. et al.: Telmisartan Randomised AssessmeNt Study I ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet 2008; 372(9644): 1174-1183.
14. Yusuf S., Diener H.C., Sacco R.L. et al.: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N. Eng. J. Med. 2008; 359(12): 1225-1237.
15. Bähr I.N., Tretter P., Krüger J. et al.: High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension 2011; 58(4): 725-732.
16. Murakami K., Wada J., Ogawa D. et al.: The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diab. Vasc. Dis. Res. 2013; 10(1): 93-96.
17. Wohl P., Krusinová E., Hill M. et al.: Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur. J. Endocrinol. 2010; 163(4): 573-583.
18. Chetty V.T., Damjanovic S., Gerstein H. et al.: Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press 2014; 23(1): 54-60.
19. Takagi H., Niwa M., Mizuno Y. et al.: Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome.
20. Lake J.E., Tseng C.H., Currier J.S. et al.: A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial.
21. Sanchis-Gomar F., Lippi G.: Telmisartan as metabolic modulator: a new perspective in sports doping? Strength Cond. Res. 2012; 26(3): 608-610.
2. Matsusaka T., Ichikawa I.: Biological functions of angiotensin and its receptors. Ann. Rev. Physiol. 59: 395-412.
3. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol. Pol. 2013; 71(supl. III): 27-118.
4. McClellan K.J., Markham A.: Telmisartan. Drugs 1998; 56: 1039-1044.
5. Yamagishi S., Takeuchi M.: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses 2005; 64(3): 476-478.
6. Yamagishi S., Nakamura K., Matsui T.: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr. Mol. Med. 2007; 7(5): 463-9.
7. Shiota A., Shimabukuro M., Fukuda D.: Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. Eur. J. Pharmacol. 2012; 692(1-3): 84-90.
8. Stangier J., Su C.A., Roth W.: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res. 2000; 28(4): 149-167.
9. Boehringer Ingelheim. Micardis (telmisartan) tablets prescribing information. Ridgefield, CT; 5 marca 2004.
10. The ONTAGRET Investigators. Telmisartan, Ramipril, or Both In Patients at High Risk for Vascular Events. N. Engl. J. Med. 2008; 358(15): 1547-1559.
11. Yusuf S., Sleight P., Pogue J.: The Heart Outcome Prevention Evaluation Study Investigators: Effect of angiotensin–converting enzyme, ramipril on cardiovascular events in high–risk patients. N. Engl. J. Med., 2000; 342: 145-153
12. Gerstein H.C., Bosch J., Pogue J. et al.: Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996; 19(11): 1225-1228.
13. Yusuf S., Teo K., Anderson C. et al.: Telmisartan Randomised AssessmeNt Study I ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet 2008; 372(9644): 1174-1183.
14. Yusuf S., Diener H.C., Sacco R.L. et al.: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N. Eng. J. Med. 2008; 359(12): 1225-1237.
15. Bähr I.N., Tretter P., Krüger J. et al.: High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension 2011; 58(4): 725-732.
16. Murakami K., Wada J., Ogawa D. et al.: The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diab. Vasc. Dis. Res. 2013; 10(1): 93-96.
17. Wohl P., Krusinová E., Hill M. et al.: Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur. J. Endocrinol. 2010; 163(4): 573-583.
18. Chetty V.T., Damjanovic S., Gerstein H. et al.: Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press 2014; 23(1): 54-60.
19. Takagi H., Niwa M., Mizuno Y. et al.: Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome.
20. Lake J.E., Tseng C.H., Currier J.S. et al.: A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial.
21. Sanchis-Gomar F., Lippi G.: Telmisartan as metabolic modulator: a new perspective in sports doping? Strength Cond. Res. 2012; 26(3): 608-610.